Clinical Trial Search

Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157

Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants

Primary: Number of Participants With Response to Treatment — 0; 3; 29; 23 participants

Primary: Best Overall Response Rate — 33 percentage of participants

Primary: Biomarkers in Blood and Archived Tissue Samples, and Their Correlation With Clinical Activity in Subjects With Advanced Renal Cell Cancer Treated With Tivozanib.

Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months

Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants

Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081

Primary: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Immune Mediated Adverse Events (IMAEs) — 4.1; 0; 0; 0 Percentage of participants

Primary: Objective Response Rate (ORR) — 25.8 percentage of participants

Primary: Objective Response Rate (ORR) — 50.6 Percentage of participants

Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants

Primary: Objective Response Rate (ORR) — 36.4; 26.7 Percentage of Participants

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Metabolic Response — 5 participants

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023

Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants

Primary: Response Rate — 8 Participants

Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants

Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants

Primary: Progression Free Survival (PFS) — 2.7; 5.2 months

Primary: Progression Free Survival (PFS) — 1.91; 3.81 months — p=0.07905

Primary: Progression-free Survival — 1.7 months

Primary: Progression-free Survival (PFS) - All Participants — 7.4 months

Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants

Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants